№ lp_1_2_66806
File format: docx
Character count: 5235
File size: 47 KB
Protocol outlining the steps required to handle and process brain tissue samples suspected of Creutzfeldt-Jakob disease (CJD) to ensure safe handling and avoid infection.
Note:
Year
Subject:
Neuropathology, Prion Diseases
Document Type:
Procedure
Organization / Institution:
National Prion Disease Pathology Surveillance Center
Author:
Chad Patete for Dr. Gambetti
Target Audience:
Neuropathologists, Medical Staff
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
Winnipeg, Manitoba
Subject:
Creutzfeldt-Jakob Disease, CSF testing
Document Type:
Procedure
Organization / Institution:
National Microbiology Laboratory for Health Canada
Author:
Not specified
Target Audience:
Laboratory staff, healthcare professionals
Period of Validity:
Indefinite
Approval Date:
Not specified
Modification Date:
Not specified
Related Documents:
MIC-10.5.1.1 Appendix I – Risk Assessment for CJD, PRM-5.30.0.0, PRM-5.30.1.4.3, SAF-10.4.11
Sample Requirements:
CSF samples, minimum of 2-3 mL
Safety Instructions:
Biological Safety Cabinet (BSC), single-use protective equipment, dry ice
Procedure Details:
Testing procedure for Creutzfeldt-Jakob Disease (CJD) with safety and specimen handling protocols
Context:
Procedure document outlining the testing and safety protocols for CJD diagnosis through CSF analysis at a national laboratory
Year:
2027
Region / City:
Texas
Topic:
Criminal Justice, Grants
Document Type:
Application Form
Agency / Organization:
Office of the Governor-Public Safety Office/Criminal Justice Division (CJD)
Author:
ATCOG CJ Staff
Target Audience:
Agencies or organizations applying for criminal justice grants
Period of Action:
FY2027
Approval Date:
January 12, 2026
Date of Changes:
N/A
Year:
2021
Region / City:
Winnipeg, Manitoba
Subject:
Creutzfeldt-Jakob Disease, CSF testing
Document Type:
Procedure
Organization / Institution:
National Microbiology Laboratory for Health Canada
Author:
Not specified
Target Audience:
Laboratory staff, healthcare professionals
Period of Validity:
Indefinite
Approval Date:
Not specified
Modification Date:
Not specified
Related Documents:
MIC-10.5.1.1 Appendix I – Risk Assessment for CJD, PRM-5.30.0.0, PRM-5.30.1.4.3, SAF-10.4.11
Sample Requirements:
CSF samples, minimum of 2-3 mL
Safety Instructions:
Biological Safety Cabinet (BSC), single-use protective equipment, dry ice
Procedure Details:
Testing procedure for Creutzfeldt-Jakob Disease (CJD) with safety and specimen handling protocols
Context:
Procedure document outlining the testing and safety protocols for CJD diagnosis through CSF analysis at a national laboratory
Year:
2021
Region / City:
Australia
Topic:
Creutzfeldt-Jakob disease, prion disease surveillance
Document type:
Research report
Organization / Institution:
Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR)
Author:
Christiane Stehmann, Matteo Senesi, Shannon Sarros, Amelia McGlade, Victoria Lewis, Marion Simpson, Genevieve Klug, Catriona McLean, Colin L Masters, Steven Collins
Target audience:
Healthcare professionals, researchers
Period of validity:
1 January 1970 – 31 December 2021
Date of approval:
Not specified
Date of changes:
Not specified
Year:
2023
Region / City:
Australia
Topic:
Prion Diseases Surveillance
Document Type:
Research Report
Organization:
Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR)
Authors:
Christiane Stehmann, Matteo Senesi, Shannon Sarros, Amelia McGlade, Victoria Lewis, Laura Ellett, Daniel Barber, Marion Simpson, Genevieve Klug, Catriona McLean, Colin L Masters, Steven Collins
Target Audience:
Healthcare professionals, researchers in the field of prion diseases
Period of Action:
2022
Date of Approval:
26/06/2023
Date of Updates:
31/12/2022
Abstract:
The report provides an update on the national surveillance activities for Creutzfeldt-Jakob disease and other prion diseases in Australia, summarizing case notifications, classifications, and incidence for the year 2022, with detailed findings from diagnostic tests and neuropathological assessments.
Year:
2021
Region / City:
International
Topic:
Soft tissue sarcoma histopathology
Document Type:
Guide
Organization / Institution:
International Collaboration on Cancer Reporting (ICCR)
Author:
Not specified
Target Audience:
Pathologists, oncologists, medical professionals
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Version:
1.2.0.0
Protocol posting date:
March 2023
Document type:
Clinical pathology protocol
Medical field:
Breast pathology, oncology
Procedures covered:
Needle biopsy, fine needle aspiration, other biopsy procedures
Tumor types included:
Invasive breast carcinoma of any type, with or without ductal carcinoma in situ
Tumor types excluded:
Ductal carcinoma in situ without invasion, Paget disease without invasion, phyllodes tumor, lymphoma, sarcoma
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Organization:
College of American Pathologists
Accreditation status:
Recommended for clinical care, not required for accreditation
Intended use:
Reporting of biopsy specimens
Updates:
Optional reporting of largest invasive focus; revised lymphatic and/or vascular invasion terminology
Note:
Year
Theme:
Neuropathology, Biopsy, Medical Guidelines
Document Type:
Guidelines
Organization / Institution:
Southmead Hospital
Target Audience:
Medical professionals, Neuropathologists
Context:
Guidelines for handling and sending nerve biopsy specimens to the Neuropathology Department for analysis and further processing.
Version:
4.2.0.0
Protocol Posting Date:
June 2024
Year:
2024
Region / city:
Not specified
Topic:
Bone tumor biopsy protocols
Document type:
Protocol
Organization / institution:
Not specified
Author:
Paari Murugan, MD, FCAP; Julie C. Fanburg-Smith, MD, FCAP; Andrew Horvai, MD, PhD; Fernanda Amary, MD, PhD; Meera Hameed, MD, FCAP; Michael J. Klein, MD
Target audience:
Clinicians and pathologists involved in biopsy procedures for bone tumors
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2017
Region / City:
Miami, Florida
Subject:
Procurement of Medical Equipment
Document Type:
Combined Synopsis/Solicitation
Agency:
Department of Veterans Affairs
Author:
Department of Veterans Affairs
Target Audience:
Service Disabled/Veteran Owned Small Businesses
Period of Effectiveness:
From January 19, 2017
Approval Date:
January 19, 2017
Modification Date:
N/A
Note:
Year
Topic:
Medical Procedure
Document Type:
Educational Material and Consent Form
Target Audience:
Patients undergoing vulvar biopsy
Contextual description:
Document providing detailed information and consent form for patients undergoing vulvar biopsy, including risks, procedure details, and alternatives.
Subject:
Lung cancer diagnosis and procedure coding
Diagnosis codes:
ICD-9 162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9; ICD-10 C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92
Procedure codes:
CPT, ICD-9 Procedure, ICD-10 Procedure
Clinical focus:
Biopsy procedures, CT scans, treatments, and post-procedural complications
Complication types:
Pneumothorax, prolonged air leak, hemorrhage, intubation/mechanical ventilation, mediastinitis, pneumonia, empyema, abscess of lung
Setting:
Inpatient and outpatient hospital care
Cost attribution rule:
Inpatient biopsies after day 2 costed at outpatient rate
Purpose:
Patient selection and identification of post-procedural complications and treatments
Coding systems referenced:
ICD-9-CM, ICD-10-CM, CPT
Version:
1
Date:
June 2014
Authors:
Annie Kao; Bryony Aldous
Approver:
Mary Glover
Document type:
Clinical competency workbook
Subject:
Punch skin biopsy training and assessment
Target audience:
Registered children’s nurses (Band 6 or above)
Purpose:
Assessment of theoretical knowledge and practical competence in punch skin biopsy
Assessment requirements:
Completion of workbook; observation of two procedures; supervised performance of four procedures; competency sign-off
Related policies:
Medication Administration Policy (2012); Consent Policy (2013); Patient Group Directions Policy (2013); Hand Hygiene (2014); Disposal of Used Sharps (2014); Management of Severe Local Anaesthetic Toxicity (2010)
Procedure scope:
Punch skin biopsy only
Clinical setting:
Trust clinical practice
Year:
Not specified
Region / City:
Not specified
Topic:
Medical procedure, prostate biopsy
Document Type:
Consent form
Author:
Not specified
Target Audience:
Patients undergoing prostate biopsy
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Context:
A medical consent form outlining the risks, benefits, and procedure of transrectal ultrasound and prostate biopsy.
Year:
2020
Region / city:
Australia
Subject:
Health / Medical Services
Document type:
Factsheet
Organization / institution:
Medicare
Author:
MBS Review Taskforce
Target audience:
Healthcare providers, patients, medical professionals
Effective period:
From 1 May 2020
Approval date:
16 April 2020
Modification date:
N/A
Sample size:
10378 patients
Medical condition:
Prostate cancer
Subgroups:
Clinically significant prostate cancer (csPCa), Insignificant prostate cancer (Ins-PCa), All prostate cancer (PCa)
Variables analyzed:
Age, PSA level, Prostate volume (PV), PSA density (PSAD), PI-RADS score
Age categories:
<50; 50–60; 60–70; 70–80; ≥80 years
PSA categories:
<10; 10–20; 20–50; 50–100; ≥100 ng/mL; Unknown
Prostate volume categories:
<30; 30–40; 40–60; ≥60 ml; Unknown
PSA density categories:
<0.1; 0.1–0.15; 0.15–0.2; ≥0.2; Unknown
Imaging classification system:
PI-RADS (Prostate Imaging-Reporting and Data System)
Data type:
Quantitative clinical characteristics with counts and percentages
Medical field:
Urology / Oncology
Document type:
Statistical table of clinical study data
Version:
4.1.0.0
Protocol Posting Date:
December 2022
Recommended Use:
Clinical care purposes
Not Required For Accreditation:
Yes
Procedures Covered:
Biopsy (core, incisional, other)
Tumor Types Covered:
Pediatric hepatoblastoma
Excluded Procedures:
Resection
Excluded Tumor Types:
Other primary malignant hepatic tumors
Authors:
Jessica L. Davis, MD; Soo-Jin Cho, MD, PhD; Grace Kim, MD; Sarangarajan Ranganathan, MD; Delores Lopez-Terrada, MD, PhD; Allison F. O’Neal, MD; Arun Rangaswami, MD
Guidance Committees:
CAP Cancer and CAP Pathology Electronic Reporting Committees
Core Data Elements:
Routinely reported
Non-Core Data Elements:
Indicated with +
Updates:
WHO 5th edition, Expert Consultation updated from Conditional to Optional
Target Audience:
Pathologists, oncologists, clinical researchers
Document Type:
Clinical protocol / case summary
Year:
2025
Region / City:
United States
Subject:
Pediatric Rhabdomyosarcoma Biopsy Procedures
Document Type:
Clinical Protocol
Organization:
College of American Pathologists (CAP)
Authors:
Jessica L. Davis, MD; Erin Rudzinski, MD; Michael Arnold, MD, PhD; Archana Shenoy, MD; Lea Surrey, MD; Aaron Weiss, DO
Target Audience:
Pathologists, Laboratory Staff
Effective Period:
June 2024 – present
Version:
5.0.0.1
Accreditation Requirements:
CAP Laboratory Accreditation Program
Procedures Covered:
Core biopsy, incisional biopsy, excisional biopsy
Tumor Types Covered:
Pediatric rhabdomyosarcoma and ectomesenchymoma variants
Excluded Procedures:
Adult rhabdomyosarcoma, tumor resections
Reporting Format:
Synoptic report with core and conditional data elements
Glossary:
Defines roles of authors and expert contributors
Contact:
[email protected]